Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS-mutated chronic myelomonocytic leukemia
G. Montalban-Bravo, F. Ma, N. Thongon, H. Yang, I. Ganan-Gomez, J. J. Rodriguez-Sevilla, V. Adema, B. Wildeman, P. P. Lockyer, Y. J. Kim, T. Tanaka, F. Darbaniyan, S. Pancholy, G. Zhang, G. Al-Atrash, , S. Colla
This study identifies MCL1 as a survival factor in RAS-mutated CMML, explaining resistance to BCL2 inhibitors and suggesting new therapeutic targets.
bioRxiv · Apr 7, 2023 · PreprintCancer Biology